Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 7,764 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study

NCT01537315
View directory record Official record
Conditions
Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
Interventions
Hydroxychloroquine, Matching Placebo
Drug · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

NCT00286455
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
50
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 2 Interventional

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

NCT00163085
View directory record Official record
Conditions
Parkinson's Disease
Interventions
NR2B NMDA Antagonist CP-101,606 (traxoprodil)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 22, 2006 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

NCT01850524
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Placebo, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
78
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Galantamine Effects on Cognitive Function in Marijuana Users

NCT00969696
View directory record Official record
Conditions
Memory
Interventions
Placebo, Galantamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 13, 2026, 6:34 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers

NCT07215923
View directory record Official record
Conditions
Thromboangiitis Obliterans (Buerger's Disease)
Interventions
ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g), Placebo
Biological · Other
Lead sponsor
Antidote Therapeutics, Inc
Industry
Eligibility
23 Years to 59 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

NCT02980224
View directory record Official record
Conditions
Dry Eye
Interventions
OmegaD, Placebo
Drug
Lead sponsor
OmegaD LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Prasugrel Versus Placebo in Adult Sickle Cell Disease

NCT01167023
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Prasugrel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Not applicable Interventional Results available

Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania

NCT02059980
View directory record Official record
Conditions
Obsessive Compulsive Disorder, Trichotillomania
Interventions
Response inhibition training, Placebo Control Training
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 13, 2026, 6:34 PM EDT
Active, not recruiting Early Phase 1 Interventional

Diclofenac as a KMO Inhibitor

NCT06029296
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Diclofenac, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

NCT03473223
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apolipoprotein A-I [human] (apoA-I), Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
18,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
202
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

NCT02633020
View directory record Official record
Conditions
Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
Interventions
AMG 714, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules

NCT04567524
View directory record Official record
Conditions
Schizophrenia Schizoaffective
Interventions
LYN-005
Drug
Lead sponsor
Lyndra Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Long Beach, California • Atlanta, Georgia • Marlton, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 13, 2026, 6:34 PM EDT
Withdrawn Phase 2 Interventional

Melatonin Supplementation to Improve Sleep in Patients With Heart Failure

NCT00869869
View directory record Official record
Conditions
Heart Failure, Sleep Disorders
Interventions
melatonin, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease

NCT01389024
View directory record Official record
Conditions
Sickle Cell Disease, Stroke
Interventions
Hydroxyurea, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Months to 54 Months
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Baltimore, Maryland • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 13, 2026, 6:34 PM EDT
Not listed Phase 3 Interventional

Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain

NCT00237523
View directory record Official record
Conditions
Fibrocystic Disease of Breast, Fibrocystic Changes of Breast, Fibrocystic Mastopathy, Pain
Interventions
IoGen (molecular iodine)
Drug
Lead sponsor
Symbollon Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
39
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2007 · Synced Oct 13, 2026, 6:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

NCT06775379
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Azetukalner, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder

NCT00467428
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
NS2359, Placebo
Drug
Lead sponsor
NeuroSearch A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2007 · Synced Oct 13, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease

NCT01442363
View directory record Official record
Conditions
Perianal Crohn's Disease
Interventions
BLI-1300 low dose, BLI-1300 high dose, placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
17
States / cities
Anaheim, California • San Francisco, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

NCT01991587
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 2 Interventional

Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy

NCT01019187
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Quality of Life Assessment, Questionnaire Administration, Placebo, Fatigue assessment and management, Sleep disorder therapy, Armodafinil, Management of Therapy, Cognitive Assessment, Management of therapy and complications, Fatifue assessment and management
Procedure · Other · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 2 Interventional

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

NCT02067793
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NRX-1074 1 mg, Placebo, NRX-1074 5 mg, NRX-1074 10 mg
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Oakland, California • Skokie, Illinois • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 13, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Anti-viral Therapy in Alzheimer's Disease

NCT03282916
View directory record Official record
Conditions
Alzheimer Disease, Herpes Simplex 1, Herpes Simplex 2
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 95 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 13, 2026, 6:34 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

NCT04641442
View directory record Official record
Conditions
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Interventions
MAS825, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
4
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 6:34 PM EDT